Navigation Links
CardioGenics to File for 510K Clearance With the United States Food and Drug Administration by Q4 2011
Date:2/3/2011

MISSISSAUGA, Ontario, Feb. 3, 2011 /PRNewswire/ -- CardioGenics Holdings Inc. (CGNH.OB) announced today final plans for testing of its QL Care™ (QLCA) Analyzer. The data that will be collected from the testing at 4 hospitals in North America will be used as a key component of the Company's 510K application with the United States Food and Drug Administration. The 510K application will allow the FDA to determine whether the QLCA is equivalent to another device that is currently approved by the FDA for commercialization.  Upon approval of the application, CardioGenics will begin marketing the QLCA throughout the United States.

The Company has determined that it will use the Siemens ADVIA Centaur Analyzer and its related Troponin-I test as the reference standard for its clinical testing. CardioGenics has already identified four hospitals that use the Siemens ADVIA Centaur and will obtain approval from these hospitals to conduct comparative clinical testing of its QL Care™ Analyzer and Troponin-I test at their sites. The goal of this comparative testing is to confirm that the results from the CardioGenics QL Care™ Analyzers and the Siemens ADVIA Centaur systems are equivalent. CardioGenics expects to begin enrolling patients in this comparative trial upon approval of the Institutional Review Boards, which approvals it expects to receive by May 2011. The comparative trials will take approximately 45 days to complete.

Upon successful completion of clinical confirmation, the Company will then finalize protocols and commence trials for the FDA application for approval of its QL Care™ Analyzer and Troponin-I test. This final testing is expected to start during early Q3 2011 and complete two months later.

Yahia Gawad, MD, Chief Executive Officer of CardioGenics Holdings Inc. said, "Over the past few months, we have completed development of the QL Care™ Analyzer. We have solved many of the technological challenges that
'/>"/>

SOURCE CardioGenics Holdings Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CardioGenics Holdings Inc. Provides Update on FINRA Submission Regarding Name Change
2. CardioGenics Holdings Inc. Announces Letter to Shareholders
3. CardioGenics Announces Completion of Cartridge Design for QL Care Analyzer
4. CardioGenics Holdings Inc. Featured in Medical Device Daily
5. Dr. Yahia Gawad, CEO of CardioGenics Holdings, Inc., Interviewed in MedTech Executive
6. CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads
7. CardioGenics Announces Further Update Regarding Status of Merck Agreement
8. CardioGenics Announces Lock-Up Agreement with Dr. Yahia Gawad
9. CardioGenics to be Spotlighted in Three Publications During Month of April
10. CardioGenics Announces Update Regarding Status of Merck Agreement
11. CardioGenics Announces Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , July 6, 2015 Celtaxsys, Inc., a ... including those with rare and orphan inflammatory disease indications, ... U.S. Food and Drug Administration (FDA) to begin a ... acebilustat (CTX-4430), in adult CF patients in the US. ... Europe will be filed soon after. ...
(Date:7/6/2015)...  OncoSec Medical Inc. ("OncoSec") (NASDAQ: ONCS ), ... the appointment of Joann V. Lofgren to ... Development, effective July 6, 2015. In this role, Ms. ... on the company,s market and product development strategy for ... welcome Joann to the OncoSec team and have her ...
(Date:7/4/2015)... 4, 2015 De ... chemotherapie voor patiënten met niet-resectabele uitgezaaide colorectale ... progressievrije overleving in dat orgaan. ... (mCRC) die alleen binnen de lever is ... overleving (PFS) in de lever dankzij de ...
Breaking Medicine Technology:Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 2OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 3Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 2Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 3Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 4Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 5
... Mass., Aug. 14 StatSure,Diagnostic Systems, Inc. (OTC Bulletin ... patented, "barrel- test" format for the detection of,antibodies to ... completed,the trials needed for a CLIA waiver application and ... Food & Drug Administration (FDA) for,their review. The Company ...
... Efficacy of LBH589 in ... Myeloma, NORWALK, Conn., Aug. 14 The Multiple ... Phase II,study to determine the efficacy of LBH589 for ... LBH589 is an orally,administered deacetylase inhibitor developed by Novartis ...
Cached Medicine Technology:CLIA Waiver Submitted for Rapid HIV Test Employs StatSure's 'Barrel' Technology 2CLIA Waiver Submitted for Rapid HIV Test Employs StatSure's 'Barrel' Technology 3Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor 2Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor 3
(Date:7/6/2015)... New York, NY (PRWEB) , ... July 06, ... ... receive their health care from nurses or midwives, yet there is a large ... clinical nursing and midwifery research required to improve health outcomes and reduce unnecessary ...
(Date:7/6/2015)... , ... July 06, 2015 , ... Olive Fertility Centre ... UBC 2014-2015 Post Graduate Teaching Award on behalf of the department of Family Practice. ... very exciting field to be practicing in. The technology is changing so rapidly and ...
(Date:7/6/2015)... Irvine, CA (PRWEB) , ... July 06, 2015 ... ... for disease prevention in southern California, has partnered with Woodbridge Walk-In Urgent Care ... disease, cancer, stroke and other serious medical conditions. Screenings are affordable and accurate ...
(Date:7/6/2015)... Aspen, CO (PRWEB) , ... July 06, 2015 , ... ... now, and the ability of the medical field to access and use this “Big ... L. Davis, MD, President and Chief Executive Officer of the Mount Sinai Health System ...
(Date:7/6/2015)... ... ... In a split second, breaking a bone can cause loss of freedom ... through the bone health screenings conducted by American Bone Health trained Peer Educators during ... need this information to remain independent and strong for many more years,” according to ...
Breaking Medicine News(10 mins):Health News:Columbia Nursing Nairobi Summit: Setting a Clinical Research Agenda for Africa 2Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:Woodbridge Walk-In Offers Affordable Early Detection Health Screenings Through Longevity 2Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 2Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 3Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 4Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 5Health News:National Bone Health Screening and Awareness Day 2
... fish during pregnancy may increase the risk of premature ... mercury levels in oily fish like mackerel, salmon and ... say that it is essential for everybody including pregnant ... ,According to the Food Standards Agency, pregnant women ...
... that women at different work places were at higher risk ... have grown up// on a farm have a risk of ... ,The study also found out that women working ... risk for breast cancer than the national average.,This study, conducted ...
... kind of war for Prem Khullar. Here you don't shed ... populations//. And the retired air force squadron leader has been ... ,What began in 1993 as a one-room clinic is today ... through generous NRI funding and local land donations, it has ...
... mind works in old age depends on physical fitness and ... published in the October 10, 2006, issue of Neurology//, the ... ,In determining whether physical fitness is associated with more successful ... had been participants of the Scottish Mental Survey of 1932. ...
... kn,owledge of the cervical cancer virus, in spite of the fact ... some point// in their lives, it was revealed today. ,A ... virus. ,Estimates have shown that Ireland has one of the ... cases of pre-cancer cells found each year with around 200 cases ...
... in Atlanta has offered an insight into the calcium levels ... low calcium in new borns is an outcome of high ... certain difficulties, which may include deficient bone formation. ,To ... Hospital Center in New York analyzed the children of mothers, ...
Cached Medicine News:Health News:Premature Delivery due to Oily fish 2Health News:Threat of Cervical Cancer Unknown to Most Women 2
... with a low-profile, roomy pouch to ... site during arthroscopic surgery. Available with ... drainage. , ,The arthroscopy sheets ... pack, or in custom trays. For ...
The Abbott Commander is an automated, high-throughput immunoassay testing system. The Commander System consists of the Flexible Pipetting Center, the Parallel Processing Center, and the Dynamic Incub...
... Sequence Detection System is a complete, ... quantitates nulceic acid sequences. In real-time ... product is made possible by combining ... software in a single instrument. Quantitative ...
... CELL-DYN 3200 sets a benchmark of ... scatter for WBC, RBC, PLT and ... the needs of today's laboratory. The ... differential analysis, automated sample handling, comprehensive ...
Medicine Products: